Adjuncts to dopamine replacement : A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease
Identifieur interne :
002F36 ( PascalFrancis/Corpus );
précédent :
002F35;
suivant :
002F37
Adjuncts to dopamine replacement : A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease
Auteurs : J. M. BrotchieSource :
-
Movement disorders [ 0885-3185 ] ; 1998.
RBID : Pascal:99-0010787
Descripteurs français
- Pascal (Inist)
- Parkinson maladie,
Dyskinésie,
Lévodopa,
Antiparkinsonien,
Antagoniste,
Récepteur NMDA,
Chimiothérapie,
Traitement,
Homme,
Récepteur opiacé,
Récepteur adrénergique.
English descriptors
- KwdEn :
- Adrenergic receptor,
Antagonist,
Antiparkinson agent,
Chemotherapy,
Dyskinesia,
Human,
Levodopa,
NMDA receptor,
Opioid receptor,
Parkinson disease,
Treatment.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
| A01 | 01 | 1 | | @0 0885-3185 |
|---|
| A03 | | 1 | | @0 Mov. disord. |
|---|
| A05 | | | | @2 13 |
|---|
| A06 | | | | @2 6 |
|---|
| A08 | 01 | 1 | ENG | @1 Adjuncts to dopamine replacement : A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease |
|---|
| A11 | 01 | 1 | | @1 BROTCHIE (J. M.) |
|---|
| A14 | 01 | | | @1 Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester @3 GBR @Z 1 aut. |
|---|
| A20 | | | | @1 871-876 |
|---|
| A21 | | | | @1 1998 |
|---|
| A23 | 01 | | | @0 ENG |
|---|
| A43 | 01 | | | @1 INIST @2 20953 @5 354000071406360020 |
|---|
| A44 | | | | @0 0000 @1 © 1999 INIST-CNRS. All rights reserved. |
|---|
| A45 | | | | @0 14 ref. |
|---|
| A47 | 01 | 1 | | @0 99-0010787 |
|---|
| A60 | | | | @1 P |
|---|
| A61 | | | | @0 A |
|---|
| A64 | | 1 | | @0 Movement disorders |
|---|
| A66 | 01 | | | @0 USA |
|---|
| C02 | 01 | X | | @0 002B02B09G |
|---|
| C03 | 01 | X | FRE | @0 Parkinson maladie @5 01 |
|---|
| C03 | 01 | X | ENG | @0 Parkinson disease @5 01 |
|---|
| C03 | 01 | X | SPA | @0 Parkinson enfermedad @5 01 |
|---|
| C03 | 02 | X | FRE | @0 Dyskinésie @5 04 |
|---|
| C03 | 02 | X | ENG | @0 Dyskinesia @5 04 |
|---|
| C03 | 02 | X | SPA | @0 Disquinesia @5 04 |
|---|
| C03 | 03 | X | FRE | @0 Lévodopa @5 07 |
|---|
| C03 | 03 | X | ENG | @0 Levodopa @5 07 |
|---|
| C03 | 03 | X | SPA | @0 Levodopa @5 07 |
|---|
| C03 | 04 | X | FRE | @0 Antiparkinsonien @5 08 |
|---|
| C03 | 04 | X | ENG | @0 Antiparkinson agent @5 08 |
|---|
| C03 | 04 | X | SPA | @0 Antiparkinsoniano @5 08 |
|---|
| C03 | 05 | X | FRE | @0 Antagoniste @5 10 |
|---|
| C03 | 05 | X | ENG | @0 Antagonist @5 10 |
|---|
| C03 | 05 | X | SPA | @0 Antagonista @5 10 |
|---|
| C03 | 06 | X | FRE | @0 Récepteur NMDA @5 13 |
|---|
| C03 | 06 | X | ENG | @0 NMDA receptor @5 13 |
|---|
| C03 | 06 | X | SPA | @0 Receptor NMDA @5 13 |
|---|
| C03 | 07 | X | FRE | @0 Chimiothérapie @5 16 |
|---|
| C03 | 07 | X | ENG | @0 Chemotherapy @5 16 |
|---|
| C03 | 07 | X | SPA | @0 Quimioterapia @5 16 |
|---|
| C03 | 08 | X | FRE | @0 Traitement @5 17 |
|---|
| C03 | 08 | X | ENG | @0 Treatment @5 17 |
|---|
| C03 | 08 | X | GER | @0 Aufbereiten @5 17 |
|---|
| C03 | 08 | X | SPA | @0 Tratamiento @5 17 |
|---|
| C03 | 09 | X | FRE | @0 Homme @5 20 |
|---|
| C03 | 09 | X | ENG | @0 Human @5 20 |
|---|
| C03 | 09 | X | SPA | @0 Hombre @5 20 |
|---|
| C03 | 10 | X | FRE | @0 Récepteur opiacé @5 23 |
|---|
| C03 | 10 | X | ENG | @0 Opioid receptor @5 23 |
|---|
| C03 | 10 | X | SPA | @0 Receptor opiáceo @5 23 |
|---|
| C03 | 11 | X | FRE | @0 Récepteur adrénergique @5 24 |
|---|
| C03 | 11 | X | ENG | @0 Adrenergic receptor @5 24 |
|---|
| C03 | 11 | X | SPA | @0 Receptor adrenérgico @5 24 |
|---|
| C07 | 01 | X | FRE | @0 Système nerveux pathologie @5 37 |
|---|
| C07 | 01 | X | ENG | @0 Nervous system diseases @5 37 |
|---|
| C07 | 01 | X | SPA | @0 Sistema nervioso patología @5 37 |
|---|
| C07 | 02 | X | FRE | @0 Système nerveux central pathologie @5 38 |
|---|
| C07 | 02 | X | ENG | @0 Central nervous system disease @5 38 |
|---|
| C07 | 02 | X | SPA | @0 Sistema nervosio central patología @5 38 |
|---|
| C07 | 03 | X | FRE | @0 Encéphale pathologie @5 39 |
|---|
| C07 | 03 | X | ENG | @0 Cerebral disorder @5 39 |
|---|
| C07 | 03 | X | SPA | @0 Encéfalo patología @5 39 |
|---|
| C07 | 04 | X | FRE | @0 Extrapyramidal syndrome @5 40 |
|---|
| C07 | 04 | X | ENG | @0 Extrapyramidal syndrome @5 40 |
|---|
| C07 | 04 | X | SPA | @0 Extrapiramidal síndrome @5 40 |
|---|
| C07 | 05 | X | FRE | @0 Maladie dégénérative @5 41 |
|---|
| C07 | 05 | X | ENG | @0 Degenerative disease @5 41 |
|---|
| C07 | 05 | X | SPA | @0 Enfermedad degenerativa @5 41 |
|---|
| C07 | 06 | X | FRE | @0 Trouble neurologique @5 46 |
|---|
| C07 | 06 | X | ENG | @0 Neurological disorder @5 46 |
|---|
| C07 | 06 | X | SPA | @0 Trastorno neurológico @5 46 |
|---|
| C07 | 07 | X | FRE | @0 Mouvement involontaire @5 47 |
|---|
| C07 | 07 | X | ENG | @0 Involuntary movement @5 47 |
|---|
| C07 | 07 | X | SPA | @0 Movimiento involuntario @5 47 |
|---|
| N21 | | | | @1 004 |
|---|
|
|---|
Format Inist (serveur)
| NO : | PASCAL 99-0010787 INIST |
|---|
| ET : | Adjuncts to dopamine replacement : A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease |
|---|
| AU : | BROTCHIE (J. M.) |
|---|
| AF : | Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester/Royaume-Uni (1 aut.) |
|---|
| DT : | Publication en série; Niveau analytique |
|---|
| SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1998; Vol. 13; No. 6; Pp. 871-876; Bibl. 14 ref. |
|---|
| LA : | Anglais |
|---|
| CC : | 002B02B09G |
|---|
| FD : | Parkinson maladie; Dyskinésie; Lévodopa; Antiparkinsonien; Antagoniste; Récepteur NMDA; Chimiothérapie; Traitement; Homme; Récepteur opiacé; Récepteur adrénergique |
|---|
| FG : | Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Trouble neurologique; Mouvement involontaire |
|---|
| ED : | Parkinson disease; Dyskinesia; Levodopa; Antiparkinson agent; Antagonist; NMDA receptor; Chemotherapy; Treatment; Human; Opioid receptor; Adrenergic receptor |
|---|
| EG : | Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Neurological disorder; Involuntary movement |
|---|
| GD : | Aufbereiten |
|---|
| SD : | Parkinson enfermedad; Disquinesia; Levodopa; Antiparkinsoniano; Antagonista; Receptor NMDA; Quimioterapia; Tratamiento; Hombre; Receptor opiáceo; Receptor adrenérgico |
|---|
| LO : | INIST-20953.354000071406360020 |
|---|
| ID : | 99-0010787 |
|---|
Links to Exploration step
Pascal:99-0010787
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Adjuncts to dopamine replacement : A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease</title>
<author><name sortKey="Brotchie, J M" sort="Brotchie, J M" uniqKey="Brotchie J" first="J. M." last="Brotchie">J. M. Brotchie</name>
<affiliation><inist:fA14 i1="01"><s1>Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14><publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0010787</idno>
<date when="1998">1998</date>
<idno type="stanalyst">PASCAL 99-0010787 INIST</idno>
<idno type="RBID">Pascal:99-0010787</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002F36</idno>
</publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Adjuncts to dopamine replacement : A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease</title>
<author><name sortKey="Brotchie, J M" sort="Brotchie, J M" uniqKey="Brotchie J" first="J. M." last="Brotchie">J. M. Brotchie</name>
<affiliation><inist:fA14 i1="01"><s1>Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14><series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1998">1998</date>
</imprint><seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic receptor</term>
<term>Antagonist</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Dyskinesia</term>
<term>Human</term>
<term>Levodopa</term>
<term>NMDA receptor</term>
<term>Opioid receptor</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords><keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Dyskinésie</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Antagoniste</term>
<term>Récepteur NMDA</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
<term>Récepteur opiacé</term>
<term>Récepteur adrénergique</term>
</keywords><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01><fA03 i2="1"><s0>Mov. disord.</s0>
</fA03><fA08 i1="01" i2="1" l="ENG"><s1>Adjuncts to dopamine replacement : A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease</s1>
</fA08><fA11 i1="01" i2="1"><s1>BROTCHIE (J. M.)</s1>
</fA11><fA14 i1="01"><s1>Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</fA14><fA20><s1>871-876</s1>
</fA20><fA21><s1>1998</s1>
</fA21><fA23 i1="01"><s0>ENG</s0>
</fA23><fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000071406360020</s5>
</fA43><fA44><s0>0000</s0>
<s1>© 1999 INIST-CNRS. All rights reserved.</s1>
</fA44><fA45><s0>14 ref.</s0>
</fA45><fA47 i1="01" i2="1"><s0>99-0010787</s0>
</fA47><fA64 i2="1"><s0>Movement disorders</s0>
</fA64><fA66 i1="01"><s0>USA</s0>
</fA66><fC02 i1="01" i2="X"><s0>002B02B09G</s0>
</fC02><fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03><fC03 i1="02" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>04</s5>
</fC03><fC03 i1="02" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>04</s5>
</fC03><fC03 i1="02" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>04</s5>
</fC03><fC03 i1="03" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>07</s5>
</fC03><fC03 i1="03" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>07</s5>
</fC03><fC03 i1="03" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>07</s5>
</fC03><fC03 i1="04" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>08</s5>
</fC03><fC03 i1="04" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>08</s5>
</fC03><fC03 i1="04" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>08</s5>
</fC03><fC03 i1="05" i2="X" l="FRE"><s0>Antagoniste</s0>
<s5>10</s5>
</fC03><fC03 i1="05" i2="X" l="ENG"><s0>Antagonist</s0>
<s5>10</s5>
</fC03><fC03 i1="05" i2="X" l="SPA"><s0>Antagonista</s0>
<s5>10</s5>
</fC03><fC03 i1="06" i2="X" l="FRE"><s0>Récepteur NMDA</s0>
<s5>13</s5>
</fC03><fC03 i1="06" i2="X" l="ENG"><s0>NMDA receptor</s0>
<s5>13</s5>
</fC03><fC03 i1="06" i2="X" l="SPA"><s0>Receptor NMDA</s0>
<s5>13</s5>
</fC03><fC03 i1="07" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>16</s5>
</fC03><fC03 i1="07" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>16</s5>
</fC03><fC03 i1="07" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>16</s5>
</fC03><fC03 i1="08" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03><fC03 i1="08" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03><fC03 i1="08" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>17</s5>
</fC03><fC03 i1="08" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03><fC03 i1="09" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03><fC03 i1="09" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03><fC03 i1="09" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03><fC03 i1="10" i2="X" l="FRE"><s0>Récepteur opiacé</s0>
<s5>23</s5>
</fC03><fC03 i1="10" i2="X" l="ENG"><s0>Opioid receptor</s0>
<s5>23</s5>
</fC03><fC03 i1="10" i2="X" l="SPA"><s0>Receptor opiáceo</s0>
<s5>23</s5>
</fC03><fC03 i1="11" i2="X" l="FRE"><s0>Récepteur adrénergique</s0>
<s5>24</s5>
</fC03><fC03 i1="11" i2="X" l="ENG"><s0>Adrenergic receptor</s0>
<s5>24</s5>
</fC03><fC03 i1="11" i2="X" l="SPA"><s0>Receptor adrenérgico</s0>
<s5>24</s5>
</fC03><fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07><fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07><fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07><fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07><fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07><fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07><fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07><fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07><fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07><fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07><fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07><fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07><fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07><fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07><fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07><fC07 i1="06" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>46</s5>
</fC07><fC07 i1="06" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>46</s5>
</fC07><fC07 i1="06" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>46</s5>
</fC07><fC07 i1="07" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>47</s5>
</fC07><fC07 i1="07" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>47</s5>
</fC07><fC07 i1="07" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>47</s5>
</fC07><fN21><s1>004</s1>
</fN21><server><NO>PASCAL 99-0010787 INIST</NO>
<ET>Adjuncts to dopamine replacement : A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease</ET>
<AU>BROTCHIE (J. M.)</AU>
<AF>Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester/Royaume-Uni (1 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1998; Vol. 13; No. 6; Pp. 871-876; Bibl. 14 ref.</SO>
<LA>Anglais</LA>
<CC>002B02B09G</CC>
<FD>Parkinson maladie; Dyskinésie; Lévodopa; Antiparkinsonien; Antagoniste; Récepteur NMDA; Chimiothérapie; Traitement; Homme; Récepteur opiacé; Récepteur adrénergique</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Trouble neurologique; Mouvement involontaire</FG>
<ED>Parkinson disease; Dyskinesia; Levodopa; Antiparkinson agent; Antagonist; NMDA receptor; Chemotherapy; Treatment; Human; Opioid receptor; Adrenergic receptor</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Neurological disorder; Involuntary movement</EG>
<GD>Aufbereiten</GD>
<SD>Parkinson enfermedad; Disquinesia; Levodopa; Antiparkinsoniano; Antagonista; Receptor NMDA; Quimioterapia; Tratamiento; Hombre; Receptor opiáceo; Receptor adrenérgico</SD>
<LO>INIST-20953.354000071406360020</LO>
<ID>99-0010787</ID>
</server>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F36 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002F36 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:99-0010787
|texte= Adjuncts to dopamine replacement : A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 |  |
